| Size | Price | Stock | Qty |
|---|---|---|---|
| 25mg |
|
||
| 50mg | |||
| Other Sizes |
| Targets |
PFM39 targets MRE11, a key component of the MRN (MRE11-RAD50-NBS1) complex involved in DNA double-strand break repair. It selectively inhibits the exonuclease activity of MRE11 without affecting its endonuclease activity. PFM39 targets MRE11 in a fashion similar to Mirin but distinct from PFM01, allowing blockage of dsDNA phosphate backbone rotation and selective inhibition of MRE11 exo-nuclease activity.
|
|---|---|
| ln Vitro |
In 1BR3-hTERT fibroblasts, PFM39 (100 μM) treatment reduces G2 double-strand break (DSB) repair following ionizing radiation (IR) [1]. PFM39 at 50 μM inhibits homologous recombination (HR), but it has no discernible effect on NHEJ[1].
In vitro, PFM39 (50 µM) acts as an MRE11 exonuclease inhibitor that effectively inhibits homologous recombination (HR) without significantly increasing NHEJ. It selectively inhibits MRE11 exonuclease activity while sparing endonuclease activity. The compound is a potent, cell-permeable Mirin analog. |
| ln Vivo |
In vivo activity data for PFM39 are not extensively detailed in the available literature. As an inhibitor of MRE11 exonuclease activity and homologous recombination, the compound would be expected to sensitize cancer cells to DNA-damaging agents in vivo. Specific in vivo efficacy data are not reported.
|
| Enzyme Assay |
Specific cell-free enzyme/receptor binding assay protocols for PFM39 involve MRE11 nuclease activity assays. Exonuclease and endonuclease activities are measured using appropriate DNA substrates. Selective inhibition of exonuclease activity is confirmed by comparing activity on exonuclease versus endonuclease substrates.
|
| Cell Assay |
In vitro cell-based assays for PFM39 use cell lines to assess inhibition of homologous recombination. Cells are treated with PFM39 (50 µM), and HR efficiency is measured using reporter assays. NHEJ efficiency is assessed to confirm that the compound does not significantly increase NHEJ. DNA damage repair pathways are evaluated.
|
| Animal Protocol |
In vivo animal studies for PFM39 are not detailed in the available literature. As an MRE11 inhibitor that blocks homologous recombination, typical in vivo evaluation would involve xenograft mouse models, with PFM39 administered alone or in combination with DNA-damaging agents to assess sensitization to radiation or chemotherapy.
|
| ADME/Pharmacokinetics |
PFM39 has a molecular formula of C10H9N3OS and a molecular weight of 219.26 g/mol. It is a Mirin analog that is cell-permeable. Purity is ≥98% (HPLC). Storage: dry, dark, at 0-4°C for short term or -20°C for long term. The compound is soluble in DMSO.
|
| Toxicity/Toxicokinetics |
Specific toxicological data for PFM39 are not detailed in the available literature. The compound is classified for research use only and is not intended for human therapeutic applications. As an MRE11 inhibitor that blocks homologous recombination, potential toxicities would relate to impaired DNA repair in normal tissues, though formal toxicological profiles are not reported.
|
| References | |
| Additional Infomation |
PFM39 (CAS 1310744-67-2) is a potent, cell-permeable Mirin analog that selectively inhibits MRE11 exonuclease activity (but not endonuclease activity). At 50 µM, it effectively inhibits homologous recombination without significantly increasing NHEJ. The compound is used in DNA repair research. No clinical trial data are available.
|
| Molecular Formula |
C10H9N3OS
|
|---|---|
| Molecular Weight |
219.262
|
| Exact Mass |
219.046
|
| CAS # |
1310744-67-2
|
| PubChem CID |
141991257
|
| Appearance |
Yellow to orange solid powder
|
| Density |
1.5±0.1 g/cm3
|
| Index of Refraction |
1.739
|
| LogP |
0.82
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
15
|
| Complexity |
319
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1=CC(=CC=C1/C=C\2/C(=O)NC(=N)S2)N
|
| InChi Key |
QXOIZYPBCJHYLN-YVMONPNESA-N
|
| InChi Code |
InChI=1S/C10H9N3OS/c11-7-3-1-6(2-4-7)5-8-9(14)13-10(12)15-8/h1-5H,11H2,(H2,12,13,14)/b8-5-
|
| Chemical Name |
(5Z)-5-[(4-aminophenyl)methylidene]-2-imino-1,3-thiazolidin-4-one
|
| Synonyms |
PFM39PFM-39
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~456.08 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (11.40 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (11.40 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.5608 mL | 22.8040 mL | 45.6080 mL | |
| 5 mM | 0.9122 mL | 4.5608 mL | 9.1216 mL | |
| 10 mM | 0.4561 mL | 2.2804 mL | 4.5608 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
